MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

101.32 2.57

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

97.45

Max

101.32

Galvenie mērījumi
By Trading Economics
Ienākumi	19M 424M
Pārdošana	150M 1.4B
P/E Sektora vidējais	16.829 88.032
Peļņas marža	31.052
Darbinieki	2,617
EBITDA	-75M 507M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+2.39% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.3B 19B
Iepriekšējā atvēršanas cena	98.75
Iepriekšējā slēgšanas cena	101.32

Ziņu noskaņojums

By Acuity

37%

63%

104 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. janv. 22:45 UTC

Galvenie tirgus virzītāji

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026. g. 2. janv. 22:13 UTC

Tirgus saruna

Peļņas

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 21:07 UTC

Peļņas

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2026. g. 2. janv. 20:09 UTC

Tirgus saruna

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2026. g. 2. janv. 19:48 UTC

Tirgus saruna

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2026. g. 2. janv. 17:56 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2026. g. 2. janv. 17:50 UTC

Tirgus saruna

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2026. g. 2. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 16:33 UTC

Tirgus saruna

Remittances to Mexico Fell 5.7% in November -- Market Talk

2026. g. 2. janv. 16:18 UTC

Tirgus saruna

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2026. g. 2. janv. 15:48 UTC

Peļņas

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2026. g. 2. janv. 15:17 UTC

Tirgus saruna

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2026. g. 2. janv. 15:01 UTC

Tirgus saruna

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2026. g. 2. janv. 15:00 UTC

Peļņas

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2026. g. 2. janv. 14:56 UTC

Tirgus saruna

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. janv. 14:13 UTC

Tirgus saruna

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2026. g. 2. janv. 13:39 UTC

Tirgus saruna

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2026. g. 2. janv. 13:01 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2026. g. 2. janv. 12:45 UTC

Tirgus saruna

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2026. g. 2. janv. 11:48 UTC

Tirgus saruna

European Gas Climbs as Cold Weather Bites -- Market Talk

2026. g. 2. janv. 11:36 UTC

Tirgus saruna

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2026. g. 2. janv. 11:30 UTC

Tirgus saruna

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2026. g. 2. janv. 11:29 UTC

Tirgus saruna

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2026. g. 2. janv. 11:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

2.39% augšup

Prognoze 12 mēnešiem

Vidējais 101.13 USD 2.39%

Augstākais 125 USD

Zemākais 73 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

104 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation